Immunology Data on PV-10 to Be Presented at the American Association for Cancer Research Annual Meeting
Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
announces that mechanism data on the induction of tumor specific
immunity after intralesional PV-10 treatment will be presented by
researchers from Moffitt Cancer Center and the University of South
Florida in a poster presentation at the American Association for Cancer
Research Annual Meeting in Washington, DC.
The poster, based upon abstract #1248 entitled "Intralesional Injection
with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine
Models of Breast Cancer and Melanoma," authored by Shari A.
Pilon-Thomas, Amy Weber, Krithika Kodumudi, Lisa Kuhn, Paul Toomey, Amod
Sarnaik, will be presented on April 8, 2013, from 1:00 p.m. - 5:00 p.m.
in Hall A-C, Poster Section 5, Poster #28.
Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, “The
researchers at Moffitt are providing valuable insights into how PV-10
harnesses the immune system in specific response to the injected tumor.
Although the study being presented was done in murine models of melanoma
and breast cancer, the currently open clinical trial at Moffitt is
designed to investigate this mechanism in melanoma patients. We are
pleased to enhance our understanding of intralesional PV-10 and its
potential to produce a systemic benefit in cancer patients.”
PV-10 is Provectus Pharmaceuticals' novel oncology drug designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects.
About the American Association for Cancer Research
The AACR is the oldest and largest scientific organization in the world
focused on every aspect of high-quality, innovative cancer research. Its
reputation for scientific breadth and excellence attract the premier
researchers in the field. The programs and services of the AACR foster
the exchange of knowledge and new ideas among scientists dedicated to
cancer research, provide training opportunities for the next generation
of cancer researchers, and increase public understanding of cancer.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and
dermatology therapies. Its novel oncology drug PV-10 is designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects. Its oncology focus is on melanoma, breast cancer and cancers of
the liver. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications. Its
dermatological drug PH-10 also targets abnormal or diseased cells, with
the current focus on psoriasis and atopic dermatitis. Provectus has
recently completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date thereof.
